Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Jefferson Research
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Auxilium Pharmaceuticals Inc Raises FY 2012 Guidance
Auxilium Pharmaceuticals Inc announced that it is increasing its fiscal 2012 guidance for total net revenues from the previously stated guidance of a range of $293 million to $315 million to a range of $310 million to $332 million and is also increasing fiscal 2012 net income guidance from the previously stated guidance of a range of $(5) million to $(10) million to a range of $0 million to $5 million for fiscal 201.
Latest Developments for Auxilium Pharmaceuticals Inc
- Auxilium Pharmaceuticals Inc Raises FY 2013 Guidance-Conference Call
- Auxilium Pharmaceuticals Inc Completes Acquisition Of Actient Holdings LLC
- Auxilium Pharmaceuticals Inc Announces Positive Top-Line Data From XIAFLEX Frozen Shoulder Syndrome Phase IIa Study
- Auxilium Pharmaceuticals Inc Reaffirms FY 2013 Guidance-Conference Call
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters